FDA PreCheck’s First Seven: Domestic Capacity and CGT Manufacturing Are Moving From Talk to Facility Buildouts

The FDA’s first PreCheck cohort makes one thing clear: U.S. drug facility construction is no longer a policy talking point. It is a live build-and-review pipeline. In late June 2026, the agency selected seven companies—including Eli Lilly, Regeneron, Fujifilm, Cellares, and Kriya Therapeutics—for its PreCheck pilot, aimed at accelerating domestic manufacturing capacity and shortening the path from plant design to product review.

For biopharma manufacturing leaders, health-system cell and gene therapy (CGT) and specialty pharmacy owners, and temperature-controlled logistics partners, the signal is operational. Faster facility engagement changes when capacity comes online, how limited-distribution networks form, and how cold-chain partners must scale beside new plants—not after them.

PreCheck is a voluntary pathway for companies building new U.S. drug manufacturing sites. Trade reporting on the June 2026 selections notes that the FDA drew the seven participants from a pool of more than 80 applicants. Each company has a specific facility under construction and has committed to filing an NDA, BLA, ANDA, or a supplement that relies on that new plant.

The program uses two phases:

1. Phase 1 — facility readiness: Earlier technical and regulatory feedback while the site is still being designed, built, or prepared for production—before a drug application is submitted.
2. Phase 2 — application and inspection timing: Pre-submission meetings and earlier inspections during the review cycle, so manufacturing questions are less likely to surface only at a late pre-approval inspection or in a complete response letter.

Agency messaging cited in coverage says the approach could cut up to 14 months off review timelines. The program launched in February 2026, framed as support for domestic production of critical medicines and a more predictable path for plants serving the U.S. market.

The pilot spans API, biologics, sterile injectables, and advanced therapies:

Three sites sit in North Carolina; New York hosts two; New Jersey and Indiana complete the map. That clustering matters for regional talent, CDMO ecosystems, and the logistics nodes that will feed hospitals and specialty pharmacies.

Cellares’ quality leadership has described PreCheck as moving manufacturing conversations “off the critical path” by years—before a facility is even operating. For sponsors depending on shared CGT platforms, that is the difference between facility readiness blocking approval and supporting it.

Health systems cannot wait for launch day to stand up CGT and breakthrough specialty programs. MedCity News coverage of pipeline planning argues that hospitals should prepare years ahead for clinical, operational, and financial impacts as cell and gene therapies, targeted biologics, and precision medicines advance.

Operational readiness is cross-functional: medical, pharmacy, legal, procurement, finance, business development, and strategy aligning on SOPs, staff training, technology updates, in-clinic workflows, and shipping and storage before a therapy is available—not months after.

PreCheck compresses the manufacturing side of that calendar. When domestic plants move through design and inspection engagement earlier, CGT program owners should expect:

Engage manufacturers early, harden operational infrastructure, use data to find eligible patients, and negotiate financial risk with payors before go-live. Those are program-owner workstreams that now run in parallel with accelerated plant reviews.

New domestic plants do not automatically mean open distribution. Many CGT and specialty products will still move through limited networks, restricted shippers, and tightly controlled sites of care. Faster facility timelines raise the stakes for partners who must qualify lanes, validate packaging, and staff excursion response before commercial batches leave the dock.

Limited-distribution access will reward organizations that can document facility understanding—material flow, segregation, and cold-chain handoffs—not only contracting speed.

As PreCheck pulls regulators into earlier facility conversations, manufacturers and their hospital and logistics partners need a shared picture of the build. Floorplans and SOP PDFs alone rarely bridge quality, engineering, pharmacy leadership, and external shippers.

3D Visualization and clear facility storytelling help teams walk a site before steel is finished: material flows, cleanroom adjacencies, cryogenic storage, and dock-to-pharmacy paths. For CGT and specialty buildouts, that shared model reduces late redesign, speeds training, and makes limited-distribution and cold-chain onboarding concrete.